Novartis chooses Massachusetts for division HQ

Novartis has chosen Cambridge, MA as the location of its global vaccines and diagnostics division. The move will add 250 new employees to the 1,300 Novartis workers already employed at the company's Boston research division. Jorg Reinhardt, CEO of the Switzerland-based company, said Novartis was looking to capitalize on the thriving biotech cluster that has grown up around the Boston area. Massachusetts doesn't do much to compete for biotech relocations, but its reputation as a research hub and as a home to one of the world's most vibrant biotech clusters still wins plenty of new jobs for the area. 

- read the report on Novartis from The Boston Globe

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.